Skip to content

The effects of calcium and vitamin B1 supplementations on premenstrual syndrome

The effects of calcium and vitamin B1 supplementation on premenstrual syndrome (PMS) in female university students: A randomized clinical controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016011810333N3
Enrollment
200
Registered
2016-02-13
Start date
2016-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: Intervention: Tablet contains 500 mg calcium carbonate and tablet contain 100 mg vitamin B1, each once a day for 8 weeks. Intervention 2: Intervention: Tablet contains 100 mg vitamin B
Treatment - Drugs
Intervention: Tablet contains 500 mg calcium carbonate and tablet contain 100 mg vitamin B1, each once a day for 8 weeks
Intervention: Tablet contains 100 mg vitamin B1, once a day for 8 weeks
Control: Tablet contains 1 mg starch powder, once a day for 8 weeks
Intervention: Tablet contains 500 mg calcium carbonate, once a day for 8 weeks

Sponsors

Ilam University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The age ranges of 18 to 30 years; having body mass index between 18.5 to 30 kg/m2; having regular menstrual cycle with 24 to 35 days interval; experiencing at least 3 symptoms of PMS questionnaire’s criteria with moderate and severe intensity during 3 consecutive period cycles; having at least 5 signs of the DMS-IV criteria for premenstrual dysphoric disorder Exclusion criteria: having any history of physical and mental illnesses; consuming anti-convulsants; consuming anti-depressants; consuming hormones and oral contraceptives; consuming multivitamin, vitamin B1 and calcium supplements during last 3 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Changes in scores of premenstrual syndrome's questionnaire. Timepoint: Before and 2 months after the start of the intervention. Method of measurement: Standard questionnaire for premenstrual syndrome.

Secondary

MeasureTime frame
Changes in scores of the premenstrual dysphoric disorder's questionnaire. Timepoint: Before and 2 months after the start of the intervention. Method of measurement: Standard questionnaire for premenstrual dysphoric disorder.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoheila Samieepour

Ilam University of Medical Sciences

sarma1364@gmail.com+98 88432232523

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026